AI-ACCELERATED DRUG DISCOVERY
Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of Phosphoserine phosphatase including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into Phosphoserine phosphatase therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of Phosphoserine phosphatase, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on Phosphoserine phosphatase. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of Phosphoserine phosphatase. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for Phosphoserine phosphatase includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Phosphoserine phosphatase
partner:
Reaxense
upacc:
P78330
UPID:
SERB_HUMAN
Alternative names:
L-3-phosphoserine phosphatase; O-phosphoserine phosphohydrolase
Alternative UPACC:
P78330; B2RCR5; Q7Z3S5
Background:
Phosphoserine phosphatase (PSP), also known as L-3-phosphoserine phosphatase or O-phosphoserine phosphohydrolase, plays a pivotal role in the biosynthesis of L-serine from carbohydrates. It catalyzes the dephosphorylation of O-phospho-L-serine to L-serine, a critical step in various metabolic pathways including protein synthesis, amino acid production, nucleotide metabolism, and glutathione synthesis. L-serine is also racemized to D-serine, a neuromodulator, highlighting PSP's multifaceted role in biological systems.
Therapeutic significance:
PSP deficiency is linked to a rare autosomal recessive disorder characterized by growth retardation, psychomotor retardation, and facial features suggestive of Williams syndrome. This association underscores the therapeutic potential of targeting PSP in treating phosphoserine phosphatase deficiency and possibly other related metabolic disorders.
